Get the Stockscreener App
10.79
4.86%
0.50
Climb Bio Inc stock is traded at $10.79, with a volume of 248.19K.
It is up +4.86% in the last 24 hours and down -22.43% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
See More
Previous Close:
$10.29
Open:
$10.32
24h Volume:
248.19K
Relative Volume:
0.25
Market Cap:
$619.74M
Revenue:
Net Income/Loss:
$-52.79M
P/E Ratio:
-13.85
EPS:
-0.7789
Net Cash Flow:
$-53.49M
1W Performance:
-0.64%
1M Performance:
-22.43%
6M Performance:
+24.74%
1Y Performance:
+456.19%
1-Day Range:
$10.25
$10.94
1-Week Range:
$10.09
$11.30
52-Week Range:
$1.635
$18.33
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
10.79 | 619.74M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
509.86 | 129.23B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.75 | 94.92B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.00 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.32 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.60 | 42.04B | 5.76B | 514.49M | 1.10B | 4.4813 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Jun-08-26 | Initiated | Guggenheim | Buy |
| May-05-26 | Initiated | Chardan Capital Markets | Buy |
| Apr-15-26 | Initiated | Mizuho | Outperform |
| Mar-24-26 | Initiated | B. Riley Securities | Buy |
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Mar-05-26 | Initiated | Wedbush | Outperform |
| Feb-13-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | William Blair | Outperform |
| Oct-13-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
View All
Climb Bio Inc Stock (CLYM) Latest News
H.C. Wainwright reiterates Climb Bio stock rating ahead of data By Investing.com - Investing.com Canada
Climb Bio, Inc. (CLYM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alpha Cognition Inc. Common Stock (ACOG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Climb Bio to present Phase 2 data on kidney disease therapies - Investing.com Nigeria
Climb Bio to Present Preliminary Phase 2 Budoprutug Data in Primary Membranous Nephropathy at ASN Kidney Week 2026 - Quiver Quantitative
Climb Bio to present Phase 2 data on kidney disease therapies - Investing.com UK
Climb Bio (NasdaqGM:CLYM) Stock Forecast & Analyst Predictions - simplywall.st
Form 4 Climb Bio Inc For: 1 October - Investing.com India
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Nigeria
Options for 70,000 shares were exercised at $1.29–$7.89 in Climb Bio (CLYM). - Stock Titan
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Australia
Nuvectis Pharma (Nasdaq:NVCT)Stock Analysis - simplywall.st
About $19 million in liabilities are extinguished after a $450,000 payment to settle litigation. - stocktitan.net
Director Stephen Thomas Sells 100,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio (CLYM) director sells 100K shares in preset plan - Stock Titan
Climb Bio (NASDAQ: CLYM) director files to sell insider stake - Stock Titan
Climb Bio presents initial Phase 1 data for CLYM116 - Traders Union
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com Nigeria
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com Canada
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com UK
H.C. Wainwright raises Climb Bio stock price target on drug data By Investing.com - Investing.com Australia
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Australia
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - Moomoo
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Nigeria
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - marketscreener.com
H.C. Wainwright raises Climb Bio stock price target on drug data - investing.com
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Canada
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com Canada
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com South Africa
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com India
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com UK
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com Nigeria
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40 - Moomoo
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Canada
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com India
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data By Investing.com - Investing.com South Africa
BTIG raises Climb Bio stock price target to $32 on phase 1 data By Investing.com - Investing.com South Africa
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Nigeria
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Canada
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com India
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com UK
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug - Yahoo Finance
Climb Bio Announces Positive Phase 1 Trial Outcomes for CLYM116 Targeting IgA Nephropathy - Kalkine Media
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Climb Bio Inc Stock (CLYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STEPHEN THOMAS | Director |
Sep 15 '26 |
Proposed Sale |
14.56 |
100,000 |
1,456,000 |
0 |
| Thomas Stephen Basil | Director |
Sep 15 '26 |
Sale |
13.67 |
100,000 |
1,366,820 |
467,969 |
| AOIFE BRENNAN | Officer |
Jun 29 '26 |
Proposed Sale |
13.17 |
30,902 |
406,968 |
0 |
| Brennan Aoife | President and CEO |
Jun 29 '26 |
Sale |
13.17 |
30,902 |
406,979 |
87,731 |
| Thomas Stephen Basil | Director |
Feb 26 '26 |
Sale |
7.01 |
16,313 |
114,289 |
154,657 |
| STEPHEN THOMAS | Director |
Feb 25 '26 |
Proposed Sale |
6.36 |
50,000 |
318,000 |
0 |
| Thomas Stephen Basil | Director |
Feb 25 '26 |
Sale |
7.00 |
33,687 |
235,964 |
170,970 |
| Thomas Stephen Basil | Director |
Feb 13 '26 |
Sale |
5.81 |
10,000 |
58,141 |
204,657 |
| Thomas Stephen Basil | Director |
Feb 12 '26 |
Sale |
5.23 |
90,000 |
470,988 |
214,657 |
| STEPHEN THOMAS | Director |
Feb 12 '26 |
Proposed Sale |
5.56 |
100,000 |
556,000 |
0 |
3.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):